UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K
 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 11, 2025
 

Anteris Technologies Global Corp.
(Exact name of registrant as specified in its charter)
 



Delaware
001-42437
99-1407174
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

Toowong Tower, Level 3, Suite 302
9 Sherwood Road
Toowong, QLD
Australia
   4066
(Address of Principal Executive Offices)
  
(Zip Code)

Registrant’s telephone number, including area code: +61 7 3152 3200

Not Applicable
(Former name or former address, if changed since last report)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:


Title of each class  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, par value $0.0001 per share
   AVR
   The Nasdaq Global Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Item 2.02.
Results of Operations and Financial Condition.
 
On August 11, 2025 USA ET (August 12, 2025 AEST), Anteris Technologies Global Corp. (the “Company”) (i) lodged the Form 10-Q for the quarter ended June 30, 2025 with a ‘Results for announcement to the market’ cover page (the “Results Announcement”) with the Australian Securities Exchange (“ASX”) and (ii) issued an ASX Announcement regarding the Company’s financial results for the quarter ended June 30, 2025, both of which include unaudited and other historical financial information for the quarter ended June 30, 2025. The Results Announcement has been prepared for the purpose of complying with the reporting requirements of the ASX. Copies of the Results Announcement and the ASX Announcement are attached as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.
 
The information in this Item 2.02, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Current Report on Form 8-K.
 
Item 9.01. 
Financial Statements and Exhibits.
 
(d) Exhibits.

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit
No.
   Description
 
Results Announcement, as filed with the ASX, for the quarter ended June 30, 2025
     
 
ASX Announcement regarding financial results for the quarter ended June 30, 2025
     
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Anteris Technologies Global Corp.
   
Date: August 11, 2025
  
   
 
By:
/s/ Wayne Paterson
 
Name:
Wayne Paterson
 
Title:
Vice Chairman and Chief Executive Officer


Exhibit 99.1


Results for announcement to the market

Name of entity: Anteris Technologies Global Corp. (“ATGC”)
ARBN: 677 960 235
Reporting period:
For the quarter ended June 30, 2025

The attached Form 10-Q Quarterly Report for the quarter ended June 30, 2025 has been filed with the U.S. Securities and Exchange Commission.  It includes the condensed consolidated financial statements which have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and are denominated in U.S. dollars.
 
The following supplementary information is provided in connection with the Form 10-Q for the purposes of compliance with ASX Listing Rule 4.2A.3 in relation to half year reports and 4.7C in relation to quarterly activity reports. This information should be read in conjunction with the Form 10-Q and is provided to satisfy the Company’s ongoing disclosure obligations under the ASX Listing Rules.
 
The Company’s results for announcement to the market are as follows:
 
    Six months to June 30,          
   

2025
US$’000
    
 
2024
US$’000
    
Change
US$’000
    
Change
%
  
Revenues from ordinary activities
    
1,174
      
1,398
      
(224
)
    
(16
%)
Loss from ordinary activities after tax
    
(42,993
)
    
(34,972
)
    
(8,021
)
    
23
%
Loss for the period attributable to members
    
(42,698
)
    
(35,057
)
    
(7,641
)
    
22
%
 
No dividend has been proposed or declared for the reporting period.
 
Details of business activities during the quarter:
 
Refer to the Form 10-Q and the “Anteris Announces Results for the Second Quarter of 2025” announcement lodged with the ASX on August 12, 2025 AEST.
 
Use of funds:
 
On December 12, 2024, our registration statement on Form S-1 relating to our initial public offering became effective pursuant to which we issued and sold 14,878,481 shares of Common Stock at a public offering price of US$6.00 per share.
 
We received net proceeds of US$80.0 million, after deducting the underwriting discounts, commissions and offering expenses and giving effect to the exercise of the underwriters’ option to purchase additional shares.  The use of proceeds from our initial public offering, as of June 30, 2025, was as follows:
 
•
US$37.6 million for the ongoing development of DurAVR® THV and the preparation and enrolment of the Pivotal Trial of DurAVR® THV for treating severe aortic stenosis; and
 
•
US $14.1 million for net working capital, v2vmedtech expenditure and other general corporate purposes including the repayment of US$6.4 million of debt including the Obsidian convertible notes and options.
 
Aggregate amount of payments to related parties and their associates:
 
During the second quarter of 2025, the aggregate amount of payments to related parties and their associates (which includes director fees, Company secretarial fees, CEO, President and CFO remuneration) was US$640 thousand.  These payments were included in cash flows from operating activities.
 
There were no payments to related parties or their associates included in cash flows from investing activities.
 
ENDS
 
1
About Anteris
 
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
 
Anteris’ lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.  DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.  The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
 
Forward-Looking Statements
 
This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts, including the objectives of and plans for Anteris’ studies and trials, the timing of the PARADIGM Trial, the goals of the expansion of the global manufacturing capacity and the sourcing of ADAPT® tissue for the DurAVR® THV in the future. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
 
Authorisation and Additional information
 
This announcement was authorised for release on the ASX by the Board of Directors.

For more information:
 
Investor Relations
Investor Relations (US)
investors@anteristech.com
mchatterjee@bplifescience.com
Debbie Ormsby
Malini Chatterjee, Ph.D.
Anteris Technologies Global Corp.
Blueprint Life Science Group
+61 1300 550 310 | +61 7 3152 3200
+1 917 330 4269

Website
www.anteristech.com
X
@AnterisTech
LinkedIn
https://www.linkedin.com/company/anteristech


2
Exhibit 99.2


 
Anteris Announces Results for the Second Quarter of 2025
 
MINNEAPOLIS, United States and BRISBANE, Australia 12 August 2025 AEST: Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercialising cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2025, and provided a corporate update.
 
Second Quarter 2025 Highlights
 

 •
130 patients implanted with the DurAVR® THV since the start of clinical development; 49 patients treated year-to-date; 21 in the quarter
 

 •
World first “double DurAVR®” implant in a patient receiving a valve-in-valve replacement in both the mitral and aortic valve positions
 

 •
Advanced preparatory work for the DurAVR® THV's global, pivotal clinical trial (the "PARADIGM Trial") including qualifying additional clinical sites (79 sites now qualified)
 

 •
Held global investigator meeting for the PARADIGM Trial  in June, with Dr. Michael J. Reardon and Professor Stephan Windecker being confirmed as Co-Chairs of the PARADIGM Trial
 

 •
Continued ongoing engagement with the FDA to progress the Investigational Device Exemption (“IDE”) for the PARADIGM Trial
 

 •
Appointed two Non-Executive Directors to the Board of Directors (Mr. David Roberts and Mr. Gregory Moss)
 
“I’m extremely pleased with the progess achieved during the second quarter as the Company enters a new phase in its life cycle. The data generated to date from 130 patients treated with DurAVR® across multiple settings, including complex anatomies, different annular sizes, bicuspids and valve-in-valve (including a double aortic and mitral replacement in the same patient) is highly compelling. By adopting a “total disease management” approach, the development of this first-in-class biomimetic transcatheter heart valve has delivered meaningful clinical benefits across a range of clinical use cases. As such, we are excited by physician enthusiasm across the globe to recruit into the PARADIGM study which is designed to further support the growing body of evidence demonstrating DurAVR® THV’s impact on patients,” said Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris.
 
Business & Operations
 
DurAVR® THV Commercialisation Update
 
Building our Clinical data – 130 patients successfully treated with the DurAVR® THV
 
Anteris has continued to expand the level of global experience and build the body of clinical evidence with the DurAVR® THV System. At the end of the Second Quarter, there were 130 patients successfully implanted with the DurAVR® THV in rolling cohorts since start of clinical development, with 49 of these patients treated in the first half of 2025 and 21 in 2Q 2025. These additional patients continue to support the strong clinical benefits of our new class of biomimetic TAVR over current commercially available TAVR platforms.
 
860 Blue Gentian Road,
Suite 340
Eagan, MN, 55121
United States
T: +1 651 493 0606
info.us@anteristech.com
Anteris Technologies Global Corp.
BRISBANE | MINNEAPOLIS | GENEVA | MALAGA
anteristech.com

Toowong Tower, Level 3, Suite 302
9 Sherwood Road, Toowong
QLD 4066, Australia
T: +61 1300 550 310
info.au@anteristech.com
ARBN: 677 960 235

Activities supporting the launch of the PARADIGM Trial
 
Over the Second Quarter, the Anteris team made considerable progress strengthening its clinical infrastructure and manufacturing capabilities in preparation for the Trial. A key focus was the qualification of trial sites, including feasibility assessments to confirm each site’s access to a suitable aortic stenosis patient population and their capacity to conduct the Trial to the highest standards. Preparatory activities, including site contracting with planned centers across the U.S., Europe and Canada, are well advanced, with 79 sites now qualified to participate.
 
In May, Anteris hosted a European Investigator Meeting for the PARADIGM Trial to facilitate operational alignment of qualified sites across the European investigator network, with participation from principal investigators at leading sites in Denmark, France, Germany, the Netherlands and Switzerland.
 
In June, Anteris hosted a Global Investigator Meeting to formally initiate activities for the PARADIGM Trial ahead of anticipated regulatory clearance. Dr. Michael J. Reardon and Professor Stephan Windecker were confirmed as the Co-Chairs of the Trial during the meeting, held in conjunction with New York Valves. These physicians provide significant clinical and trial experience in interventional cardiology and TAVR.
 
Ongoing collaborative work with the U.S. Food and Drug Administration (FDA) to progress the Investigational Device Exemption (IDE) application has been a major focus this Quarter, in addition to proactively scaling the manufacturing of all key products to meet the anticipated inventory demands of the upcoming PARADIGM Trial.
 
Corporate matters - Board appointments
 
On 10 June, Anteris appointed two seasoned executives, David Roberts and Gregory Moss, to its Board of Directors. Mr. Roberts brings extensive operational leadership experience, and Mr. Moss offers expertise in legal and corporate governance. These appointments are strategic steps to bolster the Company's leadership as it advances its clinical and commercial objectives.
 
Second Quarter 2025 Financial Results
 
The financial results for Anteris for the quarter ended June 30, 2025 are reviewed below. All amounts in $ refer to US dollars.
 
The Company’s net operating cash outflows for the six months ended June 30, 2025 were $41.0 million, in line with the increase in clinical, regulatory and manufacturing requirements to support the PARADIGM Trial. Reflecting this clinical focus, the key areas of the Company’s operating expenditure for the three months ended June 30, 2025 were as follows:
 

 •
R&D expenses were $16.3 million.
 
The key activities undertaken were the preparatory activities linked to the PARADIGM Trial, including regulatory work regarding the IDE, extensive engagement with planned investigators at clinical trial sites and the Global Investigator Meeting. Additionally, there were clinical costs associated with the enrollment of additional DurAVR® patients and further upscaling of manufacturing capabilities.
 

 •
Selling, general and administrative expenses were $5.0 million.
 
The Company held $28.4 million of cash and cash equivalents as of June 30, 2025.
 
Anteris refers to the detailed Financial Information contained in its Form 10-Q filing including the Management Discussion & Analysis and the Risks.
 
ENDS
 
 
 2
About Anteris
 
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercialising cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
 
Anteris’ lead product, the DurAVR® Transcatheter Heart Valve (THV), was designed in partnership with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow.  DurAVR® THV is made using a single piece of moulded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.  The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
 
Forward-Looking Statements
 
This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts, including the objectives of and plans for Anteris’ studies and trials, the timing of the PARADIGM Trial, the goals of the expansion of the global manufacturing capacity and the sourcing of ADAPT® tissue for the DurAVR® THV in the future. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the SEC and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, neither ATL or Anteris assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
 
Authorisation and Additional information
 
This announcement was authorised for release on the ASX by the Board of Directors.
 
For more information:
 
Investor Relations
Investor Relations (US)
investors@anteristech.com
mchatterjee@bplifescience.com
Debbie Ormsby
Malini Chatterjee, Ph.D.
Anteris Technologies Global Corp.
Blueprint Life Science Group
+61 1300 550 310 | +61 7 3152 3200
+1 917 330 4269

Website
www.anteristech.com
X
@AnterisTech
LinkedIn
https://www.linkedin.com/company/anteristech


 
 3